Cantor Fitzgerald analyst Louise Chen maintained a Buy rating on Eli Lilly & Co (NYSE: LLY) today and set a price target of $110. The company’s shares closed yesterday at $108.62, close to its 52-week high of $109.61.
“The growth prospects for LLY’s key drugs — Verzenio — as well as its pipeline assets, especially in pain, are underappreciated, in our view. Valuation Summary We use a blend of DCF and EV/EBITDA analysis to arrive at our 12-month PT of $110. The Disclosure Section may be found on pages 3 – 4.Valuation We use a blend of DCF and EV/EBITDA analysis to arrive at our 12-month PT of $110. Risks Greater than expected brand and/or generic competition for Lilly’s key drugs/products.”
According to TipRanks.com, Chen is a 4-star analyst with an average return of 8.1% and a 42.8% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Aridis Pharmaceuticals Inc, and Melinta Therapeutics Inc.
Eli Lilly & Co has an analyst consensus of Moderate Buy, with a price target consensus of $105.70, implying a -2.7% downside from current levels. In a report issued on September 26, J.P. Morgan also maintained a Buy rating on the stock with a $117 price target.
Based on Eli Lilly & Co’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $260 million. In comparison, last year the company earned revenue of $5.66 billion and had a net profit of $556 million.
Based on the recent corporate insider activity of 128 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.